[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606654":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":31,"locations":25,"responsibleParty":37,"collaborators":25,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":50,"maxAge":25,"enrollmentInfo":51,"targetDuration":25,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":66,"whyStopped":25,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":25},{"fullName":5,"class":6},"Institute of Liver and Biliary Sciences, India","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Medical Therapy (SMT) Group","ACTIVE_COMPARATOR","Participants will receive standard medical therapy alone, which may include nutritional support, lactulose, bowel wash, albumin, vasopressors (norepinephrine\u002Fterlipressin), antibiotics, antivirals for HBV reactivation, renal replacement therapy, and intensive care support as per institutional guidelines.",[13],"Other: Standard medical therapy (SMT)",{"label":15,"type":16,"description":17,"interventionNames":18},"SMT + Double Plasma Molecular Adsorption System (DPMAS)","EXPERIMENTAL","Participants will receive standard medical therapy plus DPMAS therapy. DPMAS involves extracorporeal liver support using two sequential hemoadsorption cartridges (BS330 ion exchange resin and HA330-II neutral macroporous adsorption resin). A minimum of 2 sessions (3-4 hours each) will be given in the first 7 days, with additional sessions if partial response is observed.",[13,19],"Device: Double Plasma Molecular Adsorption System (DPMAS)",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Standard medical therapy (SMT)","Standard medical therapy includes nutritional support (25-30 kcal\u002Fkg\u002Fday), lactulose, bowel wash, albumin, vasopressors (norepinephrine\u002Fterlipressin), antibiotics, antivirals for HBV reactivation, renal replacement therapy, and intensive care support as per institutional guidelines.",[15,9],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":25},"DEVICE","Double Plasma Molecular Adsorption System (DPMAS)","DPMAS therapy uses extracorporeal liver support with two sequential hemoadsorption cartridges (BS330 ion exchange resin and HA330-II neutral macroporous adsorption resin). Minimum 2 sessions (3-4 hours each) are performed within the first 7 days, with additional sessions if partial response is observed.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":25,"email":36},"Dr. Rakhi Maiwall, MBBS, MD, DM","CONTACT","+91 8750343085","rakhi_2011@yahoo.co.in",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Rakhi Maiwall","Professor of hepatology","100606654","double-plasma-separation-and-adsorption-in-acute-on-chronic-liver-failure-dpmas-aclf-trial-100606654",false,"NCT07178366","Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)","Impact of Double Plasma Separation and Adsorption on Patients With Acute on Chronic Liver Failure- A Prospective Open-label Randomized Controlled Trial","DPMAS-ACLF","Inclusion Criteria:\n\n* ACLF patients of any etiology with systemic inflammatory response syndrome and AARC grade II or more.\n\nExclusion Criteria:\n\n* Patients eligible for corticosteroids for severe alcohol-associated hepatitis related ACLF (other than hydrocortisone according to Surviving Sepsis Campaign Guidelines 2021 which is 50 mg iv q 6 h for management of refractory shock\n* Hepatocellular carcinoma or any extrahepatic malignancy,\n* Active fungal sepsis\n* Disseminated intravascular coagulation\n* Hemodynamic instability requiring norepinephrine \\>0.20ug\u002Fkg\u002Fmin\n* Patients with coma of non-hepatic origin\n* Patients with PaO2\u002FFiO2 ratio \\\u003C150\n* Pregnancy\n* Comorbidities associated with poor outcomes (severe cardiopulmonary disease defined by a New York Heart Association score \\>3, or oxygen\u002Fsteroid-dependent chronic obstructive pulmonary disease, chronic kidney disease) and patients with post-resection liver failure\n* Patients with fibrinogen \\\u003C110 and\u002For platelets less than 50,000\n* Patients with oliguria with urine output less than 400 ml\u002Fday\n* Lack of informed consent\n* Patient enrolled in other clinical trials","ALL","18 Years",{"count":52,"type":53},56,"ESTIMATED","INTERVENTIONAL",[56],"NA","Acute-on-chronic liver failure (ACLF) is a serious condition in which patients with chronic liver disease suddenly develop severe liver injury, leading to inflammation, organ failure, and very high short-term mortality. Standard medical treatment can help, but many patients still do poorly without liver transplantation.\n\nThis study will test whether Double Plasma Molecular Adsorption System (DPMAS), an extracorporeal blood purification therapy, can improve outcomes in ACLF patients. DPMAS works by filtering the blood through special adsorption columns that remove harmful substances such as bile acids, toxins, and inflammatory molecules.\n\nIn this randomized controlled trial, adult patients with ACLF will be randomly assigned to receive either:\n\nStandard medical therapy alone, or\n\nStandard medical therapy plus DPMAS.\n\nThe main goal is to see whether DPMAS can improve liver function and reduce disease severity within 14 days. Other outcomes include survival without liver transplant at 28 days, improvement in organ functions, reduction in inflammation, and safety of the procedure.\n\nThe study will be conducted at the Institute of Liver and Biliary Sciences (ILBS), New Delhi, India, and will enroll about 56 participants over one year.",[59],"Acute-on-Chronic Liver Failure (ACLF)",[61,62,63,64,65],"ACLF","DPMAS","Lactate","Sepsis","Liver support","NOT_YET_RECRUITING","2026-03-24",{"date":69,"type":70},"2026-03-25","ACTUAL",{"date":72,"type":53},"2026-05-10",{"date":74,"type":53},"2027-10",{"name":5,"class":6}]